🔎 Trials Near Me

Beranda › Leukemia Mieloid Akut › Ohio › Cincinnati

Uji klinis Leukemia Mieloid Akut di Cincinnati, OH

20 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi sekitar Cincinnati (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Good Samaritan Hospital - Cincinnati, Cincinnati
  • Oncology Hematology Care Inc-Kenwood, Cincinnati
  • Bethesda North Hospital, Cincinnati
  • dan 3 lainnya
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Menerima pesertaStudi observasional
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Usia 0 hingga 38 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06131801

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Menerima pesertaFase 3
  • Oncology Hematology Care, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06852222

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Menerima pesertaFase 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Hingga usia 21 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07012044

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Menerima pesertaFase 3
  • Cincinnati Children's Hospital Medical Center, Cincinnati
6 Months – 21 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04293562

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Menerima pesertaStudi observasional
  • University of Cincinnati, Cincinnati
Usia 0 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07154823

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Menerima pesertaFase 3
  • US-Cincinnati OH-CINCY, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Menerima pesertaFase 3
  • US-Cincinnati OH-CINCY, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Menerima pesertaFase 1
  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
  • University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi jauhnya
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05886049

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Menerima pesertaFase 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06177067

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Menerima pesertaFase 3
  • University of Cincinnati Medical Center (University Hospital), Cincinnati
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 17 Jul 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Menerima pesertaStudi observasional
  • Cincinnati Children's Hospital, Cincinnati
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Menerima pesertaFase 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • University of Cincinnati, Cincinnati
Usia 13 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT04771572

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Menerima pesertaFase 1
  • Cincinnati Children's Hospital, Cincinnati
Hingga usia 21 · Semua jenis kelamin · Diperbarui 22 Apr 2026 · NCT05101551

Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)

Menerima pesertaFase 1/2
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Usia 2 ke atas · Semua jenis kelamin · Diperbarui 25 Feb 2026 · NCT05580601

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Menerima pesertaFase 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Usia 1 hingga 39 · Semua jenis kelamin · Diperbarui 18 Feb 2026 · NCT03826992

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Menerima pesertaFase 2
  • Cincinnati Children's Hospital Medical Center, Cincinnati
3 Months · Semua jenis kelamin · Diperbarui 12 Nov 2025 · NCT02143830

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Menerima pesertaFase 1
  • Oncology Hematology Care, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Mei 2025 · NCT06634394

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Menerima pesertaFase 1
  • University of Cincinnati, Cincinnati
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Nov 2024 · NCT06034275

Uji klinis Leukemia Mieloid Akut di kota lain

Studi lain di Cincinnati

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.